Flecainide: Difference between revisions
No edit summary |
No edit summary |
||
| Line 18: | Line 18: | ||
==Category== | ==Category== | ||
[[Antiarrhythmic agents]];[[Piperidines]] | [[Antiarrhythmic agents]];[[Piperidines]];[[Benzamides]];[[Phenol ethers]];[[Organofluorides]];[[Sodium channel blockers]];[[Cardiovascular Drugs]] | ||
==FDA Package Insert== | ==FDA Package Insert== | ||
| Line 38: | Line 38: | ||
'''| [[Flecainide clinical studies|Clinical Studies]]''' | '''| [[Flecainide clinical studies|Clinical Studies]]''' | ||
'''| [[Flecainide how supplied storage and handling|How Supplied/Storage and Handling]]''' | '''| [[Flecainide how supplied storage and handling|How Supplied/Storage and Handling]]''' | ||
'''| [[Flecainide labels and packages|Labels and Packages]]''' | '''| [[Flecainide labels and packages|Labels and Packages]]''' | ||
Revision as of 19:13, 11 March 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]
For patient information about Flecainide, click here.
Synonyms / Brand Names: FLECAINIDE ACETATE®
 |
Overview
Flecainide acetate (/flɛˈkeɪnaɪd/ Template:USdict) is a class Ic antiarrhythmic agent used to prevent and treat tachyarrhythmias (abnormal fast rhythms of the heart). It is used to treat a variety of cardiac arrhythmias including paroxysmal atrial fibrillation (episodic irregular heartbeat originating in the upper chamber of the heart), paroxysmal supraventricular tachycardia (episodic rapid but regular heartbeat originating in the atrium), and ventricular tachycardia (rapid rhythms of the lower chambers of the heart). Flecainide works by regulating the flow of sodium in the heart, causing prolongation of the cardiac action potential.
Flecainide is sold under the trade name Tambocor (manufactured by 3M pharmaceuticals). Flecainide went off-patent on February 10, 2004. In addition to being marketed as Tambocor, it is also available in generic version and under the trade names Almarytm, Apocard, Ecrinal, and Flécaine.
Category
Antiarrhythmic agents;Piperidines;Benzamides;Phenol ethers;Organofluorides;Sodium channel blockers;Cardiovascular Drugs
FDA Package Insert
FLECAINIDE ACETATE tablet
Indications and Usage | Dosage and Administration | Dosage Forms and Strengths | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Use in Specific Populations | Overdosage | Description | Clinical Pharmacology | Nonclinical Toxicology | Clinical Studies | How Supplied/Storage and Handling | Labels and Packages
Mechanism of Action
Flecainide works by blocking the Nav1.5 sodium channel in the heart, causing prolongation of the cardiac action potential.[1] This thereby slows conduction of the electrical impulse within the heart. The greatest effect is on the His-Purkinje system and ventricular myocardium. The effect of flecainide on the ventricular myocardium causes decreased contractility of the muscle, which leads to a decrease in the ejection fraction.
The effect of flecainide on the sodium channels of the heart increases as the heart rate increases.[2] This is known as use-dependence. This means that flecainide is potentially more useful to break a tachyarrhythmia (because it has increased effect during the fast heart rate) than to prevent a bradyarrhythmia from occurring (because of its lowered effectiveness during slower heart rates).
Interaction with Alcohl
Concomitant overdose of other drugs and/or alcohol in many instances undoubtedly contributed to the fatal outcome.
References
- ↑ Ramos E, O'leary M (2004). "State-dependent trapping of flecainide in the cardiac sodium channel". J Physiol. 560 (Pt 1): 37–49. doi:10.1113/jphysiol.2004.065003. PMC 1665201. PMID 15272045.
- ↑ Wang Z, Fermini B, Nattel S (1993). "Mechanism of flecainide's rate-dependent actions on action potential duration in canine atrial tissue". J Pharmacol Exp Ther. 267 (2): 575–81. PMID 8246130.